Haemonetics Corporation (HAE)
Chart Events
Performance Outlook
| Previous Close | 67.70 |
| Open | 67.91 |
| Bid | 66.74 x 1800 |
| Ask | 66.81 x 900 |
| Day's Range | 66.39 - 68.00 |
| 52 Week Range | 66.39 - 142.11 |
| Volume | 653,454 |
| Avg. Volume | 398,638 |
| Market Cap | 3.374B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 31.32 |
| EPS (TTM) | 2.12 |
| Earnings Date | May 03, 2021 - May 07, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 117.43 |
- TheStreet.com
Haemonetics Slumps as CSL Plasma Declines to Renew a Supply Pact
About 12% of Haemonetics 2020 revenue came from a contract with CSL Plasma. CSL declined to renew the accord.
- PR Newswire
Haemonetics Provides Update On U.S. Plasma Business
Haemonetics Corporation (NYSE: HAE) ("Haemonetics" or the "Company"), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that CSL Plasma, Ltd. ("CSL") has informed Haemonetics of its intent not to renew its Supply Agreement with Haemonetics for the use of PCS2® Plasma Collection System devices and the purchase of disposable plasmapheresis kits in the U.S. following the expiration of the current term in June 2022. Haemonetics was informed that the decision was based on changes in CSL's internal strategy and was not related to product or service quality.
- Simply Wall St.
The Haemonetics (NYSE:HAE) Share Price Has Gained 233%, So Why Not Pay It Some Attention?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...
